Poolbeg Pharma PLC (LON:POLB – Get Free Report) reached a new 52-week low on Wednesday . The company traded as low as GBX 6.96 ($0.09) and last traded at GBX 7.14 ($0.09), with a volume of 463643 shares. The stock had previously closed at GBX 7.20 ($0.09).
Poolbeg Pharma Trading Down 2.0 %
The company has a market capitalization of £36.00 million, a PE ratio of -735.00 and a beta of 2.11. The business’s 50-day simple moving average is GBX 7.90 and its two-hundred day simple moving average is GBX 10.71.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Recommended Stories
- Five stocks we like better than Poolbeg Pharma
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Health Care Stocks Explained: Why You Might Want to Invest
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Choose Top Rated Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
